These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1159 related articles for article (PubMed ID: 32042148)

  • 1. Engineering adeno-associated virus vectors for gene therapy.
    Li C; Samulski RJ
    Nat Rev Genet; 2020 Apr; 21(4):255-272. PubMed ID: 32042148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune responses to adeno-associated virus vectors.
    Zaiss AK; Muruve DA
    Curr Gene Ther; 2005 Jun; 5(3):323-31. PubMed ID: 15975009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction.
    Shao W; Earley LF; Chai Z; Chen X; Sun J; He T; Deng M; Hirsch ML; Ting J; Samulski RJ; Li C
    JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innate Immune Sensing of Adeno-Associated Virus Vectors.
    Cao D; Byrne BJ; de Jong YP; Terhorst C; Duan D; Herzog RW; Kumar SRP
    Hum Gene Ther; 2024 Jul; 35(13-14):451-463. PubMed ID: 38887999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adeno-Associated Viruses (AAV) and Host Immunity - A Race Between the Hare and the Hedgehog.
    Rapti K; Grimm D
    Front Immunol; 2021; 12():753467. PubMed ID: 34777364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them.
    Hareendran S; Balakrishnan B; Sen D; Kumar S; Srivastava A; Jayandharan GR
    Rev Med Virol; 2013 Nov; 23(6):399-413. PubMed ID: 24023004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical Modifications of the Capsid for Redirecting and Improving the Efficacy of Adeno-Associated Virus Vectors.
    Lam AK; Frabutt D; Li L; Xiao W
    Hum Gene Ther; 2021 Dec; 32(23-24):1433-1438. PubMed ID: 34254844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elimination of contaminating cap genes in AAV vector virions reduces immune responses and improves transgene expression in a canine gene therapy model.
    Wang Z; Halbert CL; Lee D; Butts T; Tapscott SJ; Storb R; Miller AD
    Gene Ther; 2014 Apr; 21(4):363-70. PubMed ID: 24500525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
    Zaiss AK; Muruve DA
    Gene Ther; 2008 Jun; 15(11):808-16. PubMed ID: 18385765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy.
    Rodríguez-Márquez E; Meumann N; Büning H
    Expert Opin Biol Ther; 2021 Jun; 21(6):749-766. PubMed ID: 33331201
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer.
    Arjomandnejad M; Dasgupta I; Flotte TR; Keeler AM
    BioDrugs; 2023 May; 37(3):311-329. PubMed ID: 36862289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice.
    Zhu J; Huang X; Yang Y
    J Clin Invest; 2009 Aug; 119(8):2388-98. PubMed ID: 19587448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adeno-associated virus (AAV) vectors in cancer gene therapy.
    Santiago-Ortiz JL; Schaffer DV
    J Control Release; 2016 Oct; 240():287-301. PubMed ID: 26796040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetically Engineered Adeno-Associated Virus for Efficient, Safe, and Versatile Gene Therapy Applications.
    Lugin ML; Lee RT; Kwon YJ
    ACS Nano; 2020 Nov; 14(11):14262-14283. PubMed ID: 33073995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lethal immunotoxicity in high-dose systemic AAV therapy.
    Duan D
    Mol Ther; 2023 Nov; 31(11):3123-3126. PubMed ID: 37822079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capsid Engineering Overcomes Barriers Toward Adeno-Associated Virus Vector-Mediated Transduction of Endothelial Cells.
    Zhang L; Rossi A; Lange L; Meumann N; Koitzsch U; Christie K; Nesbit MA; Moore CBT; Hacker UT; Morgan M; Hoffmann D; Zengel J; Carette JE; Schambach A; Salvetti A; Odenthal M; Büning H
    Hum Gene Ther; 2019 Oct; 30(10):1284-1296. PubMed ID: 31407607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune responses to AAV vectors: overcoming barriers to successful gene therapy.
    Mingozzi F; High KA
    Blood; 2013 Jul; 122(1):23-36. PubMed ID: 23596044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adeno-Associated Virus Vector Design-Moving the Adeno-Associated Virus to a Bioengineered Therapeutic Nanoparticle.
    Jäschke N; Büning H
    Hematol Oncol Clin North Am; 2022 Aug; 36(4):667-685. PubMed ID: 35778330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The complex and evolving story of T cell activation to AAV vector-encoded transgene products.
    Mays LE; Wilson JM
    Mol Ther; 2011 Jan; 19(1):16-27. PubMed ID: 21119617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery.
    Nidetz NF; McGee MC; Tse LV; Li C; Cong L; Li Y; Huang W
    Pharmacol Ther; 2020 Mar; 207():107453. PubMed ID: 31836454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.